Regulatory

Amgen’s BiTE for lung cancer backed for EU approval

Pharmaphorum

Amgen's fast-growing bispecific T-cell engager Imdylltra should be cleared as a second-line therapy for small cell lung cancer, said the CHMP.

Regulatory Oncology Read full story

pharminent March 30, 2026 (Last updated: March 30, 2026)

Pharmaphorum

Amgen’s fast-growing bispecific T-cell engager Imdylltra should be cleared as a second-line therapy for small cell lung cancer, said the CHMP.

Regulatory Oncology Read full story